Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
- 29 October 2008
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (12), 1167-1177
- https://doi.org/10.1111/j.1463-1326.2008.00907.x
Abstract
Type 2 diabetes is characterized by decreases in insulin secretion and insulin sensitivity. Several classes of oral antidiabetic medications are currently approved for the treatment of type 2 diabetes. A stepwise treatment approach from monotherapy to combination therapy is traditionally used; however, the frequency of treatment failure with monotherapy has resulted in a move towards earlier treatment with combination therapies that target the two principal defects in glycaemic control. One such combination regimen is repaglinide (a prandial glucose regulator that increases insulin release) plus metformin (an insulin sensitizer that inhibits hepatic glucose output, increases peripheral glucose uptake and utilization and minimizes weight gain). Findings from several clinical trials have shown that combination therapy with repaglinide plus metformin is well tolerated and results in greater reductions of haemoglobin A(1c) and fasting plasma glucose values compared with either monotherapy. Repaglinide may also provide a more suitable alternative to combination therapy with sulphonylureas and metformin because of its reduced propensity for hypoglycaemia. The combination regimen of repaglinide plus metformin should therefore be considered as a valuable option in the management of patients with type 2 diabetes when monotherapy is no longer adequate.Keywords
This publication has 90 references indexed in Scilit:
- The DREAM trialThe Lancet, 2006
- Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin aloneDiabetic Medicine, 2006
- Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE StudyCurrent Medical Research and Opinion, 2005
- Postprandial Glucose Regulation and Diabetic ComplicationsArchives of Internal Medicine, 2004
- Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 DiabetesCurrent Medical Research and Opinion, 2004
- Clinical Pharmacokinetics of NateglinideClinical Pharmacokinetics, 2004
- Comparison of Repaglinide and Nateglinide in Combination With MetforminDiabetes Care, 2003
- Clinical Pharmacokinetics and Pharmacodynamics of RepaglinideClinical Pharmacokinetics, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998